Bioasis Establishes U.S. Presence with Office in Connecticut
October 10 2017 - 8:00AM
Business Wire
The Company also launches new website
bioasis.us
BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF;
TSX.V:BTI), a biopharmaceutical company focused on the
delivery of therapeutics across the blood-brain barrier (BBB) and
into the central nervous system for the treatment of neurological
diseases and disorders, today announced the establishment of its
U.S. office in Guilford, Conn. Additionally, the Company has
launched its new corporate website, bioasis.us.
“Establishing a strong presence in the U.S. is an important next
step in the evolution of Bioasis,” said Mark Day, Ph.D., president
and chief executive officer. “The greater New Haven area is in
close proximity to both Boston and New York. The new U.S. office
provides a physical location that is at the cross roads of pharma,
biotech and academia. It will increase the exposure of our company
and provide access to a broad pool of talent and strategic
resources.”
Following a strategic rebranding process, Bioasis has launched
its new website, bioasis.us. The new website reflects a new array
of branding elements, including xB3™, the Company’s proprietary
platform technology for the delivery of neurological treatments
across the BBB, and a modernized logo. Bioasis’ new corporate
branding is an additional step in the transformation that has been
taking place at Bioasis over the past six months.
The new Bioasis site, which has been optimized for both desktop
and mobile users, more accurately tells the company’s story and
clearly highlights the company’s mission to develop symptomatic and
disease-modifying treatments for brain-related diseases and
disorders. Visitors to the website are able to efficiently access
information on Bioasis, the xB3 platform, the Company’s in-house
development programs and other corporate information.
“Bioasis is evolving and we want all aspects of our corporate
messaging to reflect these changes moving forward,” said Dr. Day.
“Our new branding, website and office location are a part of our
move to more fully engage with potential biotech and pharmaceutical
partners, better position the company for its expansion into the
U.S. and to execute our corporate strategies for the advancement of
the xB3 platform and the opportunities that platform presents for
Bioasis and the patient community.”
About Bioasis
Bioasis Technologies Inc. is a biopharmaceutical company focused
on the delivery of therapeutics across the blood-brain barrier
(BBB) and into the central nervous system for the treatment of
neurological diseases and disorders. The delivery of therapeutics
across the BBB represents the single greatest challenge in treating
neurological disorders. The company is developing and
commercializing the xB3™ platform, Bioasis’ proprietary
blood-brain barrier delivery technology, to address unmet medical
needs in the treatment of central nervous system diseases and
disorders. The company maintains headquarters in Vancouver, Canada
with offices in Guilford, Conn., United States. Bioasis trades on
the OTCQB under the symbol “BIOAF” and on the TSX Venture Exchange
under the symbol “BTI.” For more information about the company
please visit www.bioasis.ca or www.bioasis.us. You may also
follow the company on LinkedIn, Twitter and YouTube.
Forward Looking Statements
Certain statements in this press release contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 or forward-looking information under applicable
Canadian securities legislation that may not be based on historical
fact, including without limitation statements containing the words
“believe”, “may”, “plan”, “will”, “estimate”, “continue”,
“anticipate”, “intend”, “expect” and similar expressions. Such
forward-looking statements or information involve known and unknown
risks, uncertainties and other factors that may cause our actual
results, events or developments, or industry results, to be
materially different from any future results, events or
developments express or implied by such forward-looking statements
or information. Such factors include, among others, our stage of
development, lack of any product revenues, additional capital
requirements, risk associated with the completion of clinical
trials and obtaining regulatory approval to market our products,
the ability to protect our intellectual property, dependence on
collaborative partners and the prospects for negotiating additional
corporate collaborations or licensing arrangements and their
timing. Specifically, certain risks and uncertainties that could
cause such actual events or results expressed or implied by such
forward-looking statements and information to differ materially
from any future events or results expressed or implied by such
statements and information include, but are not limited to, the
risks and uncertainties that: products that we develop may not
succeed in preclinical or clinical trials, or future products in
our targeted corporate objectives; our future operating results are
uncertain and likely to fluctuate; we may not be able to raise
additional capital; we may not be successful in establishing
additional corporate collaborations or licensing arrangements; we
may not be able to establish marketing and the costs of launching
our products may be greater than anticipated; we have no experience
in commercial manufacturing; we may face unknown risks related to
intellectual property matters; we face increased competition from
pharmaceutical and biotechnology companies; and other factors as
described in detail in our filings with the Canadian securities
regulatory authorities at www.sedar.com. Given these risks and
uncertainties, you are cautioned not to place undue reliance on
such forward-looking statements and information, which are
qualified in their entirety by this cautionary statement. All
forward-looking statements and information made herein are based on
our current expectations and we undertake no obligation to revise
or update such forward- looking statements and information to
reflect subsequent events or circumstances, except as required by
law.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171010005788/en/
Bioasis Technologies Inc.Catherine London, +1
917-763-2709Catherine@bioasis.usorGraeme Dick, +1
403-561-8989Graeme@colwellcapital.com
BiOasis Technologies (TSXV:BTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
BiOasis Technologies (TSXV:BTI)
Historical Stock Chart
From Apr 2023 to Apr 2024